Forest 2021.

Study characteristics
Notes	English title De novo renal failure and clinical outcomes of patients with critical coronavirus disease 2019 Study setting Start of study recruitment (MM/YYYY) 03/2020 End of study recruitment (MM/YYYY) 03/2020 Study design retrospective cohort Study centre(s) single centres/clinics/areas within a country Number of centres/clinics/areas NR Study setting inpatient Number of participants recruited 330 Sampling method consecutive participants Participants Female participants (absolute number), 130 Age measure, value not reported Inclusion criteria >= 18 years old, RT‐PCR+, endotracheal intubation and mechanical ventilation upon initial presentation or during inpatient hospitalisation, history of ESRD Exclusion criteria Patients who expired in the emergency department without planned hospital admission Smoking NR Diabetes (absolute number), 194 Hypertension (absolute number), 224 Cardiovascular diseases (absolute number), 55 Please indicate if additional information is available  CAD 55, CHF 55 Asthma (absolute number), 83 Chronic obstructive pulmonary disease (absolute number), 83 Other pulmonary diseases (unspecified) Please indicate if additional information is available  NR Immunosuppression (unspecified) Please indicate if additional information is available HIV 10 Chronic kidney disease (absolute number), 81 Cancer (unspecified) Steroid administration (unspecified), Supplemental oxygen (unspecified) Differential values for various oxygenation methods (if indicated) NR Other treatment NR Dose if applicable NR Duration if applicable NR Percentage received this treatment NR Prognostic factor(s) Study’s definition for obesity BMI greater than or equal to 30 The time when obesity has been measured unspecified Main variable used for determination of obesity BMI Threshold used for definition of obesity  30 Measure of frequency unspecified Frequency value NR How many eligible outcomes reported? 1 How many eligible outcomes reported? 1 Outcome(s) mortality Outcome (prognostic factor) mortality (BMI >= 30) Outcome mortality Prognostic factor (category):  BMI >= 30 Follow‐up Number of patients followed completely for this outcome  330 Number of obese patients followed completely for this outcome  unspecified Number of non‐obese patients followed completely for this outcome  unspecified Univariable (unadjusted) analysis for obesity Effect measure for obesity NR Effect measure value (95% CI) NR Multivariable (adjusted) analysis for obesity Modelling method logistic regression The set of prognostic factors used for adjustment Age (60 years old cut‐point), CVD, CKD, COPD or asthma, DM, HTN, race, renal replacement therapy, sex Effect measure for obesity NR Effect measure value (95% CI) 2.138 (1.039, 4.399)
Item	Authors' judgement	Support for judgement
Study Participation	Yes	Appendix 3
Study Attrition Mortality	Yes	Appendix 3
Prognostic Factor Measurement	Yes	Appendix 3
Outcome Measurement Mortality	Yes	Appendix 3
Confounding Bias Mortality	Yes	Appendix 3
Statistical Analysis Bias	Yes	Appendix 3